Does the media favor AGIO or CCCC?

In the previous week, Agios Pharmaceuticals had 8 more articles in the media than C4 Therapeutics. MarketBeat recorded 12 mentions for Agios Pharmaceuticals and 4 mentions for C4 Therapeutics. Agios Pharmaceuticals' average media sentiment score of 0.76 beat C4 Therapeutics' score of 0.24 indicating that Agios Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive C4 Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CCCC or TSHA?

In the previous week, C4 Therapeutics had 1 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 4 mentions for C4 Therapeutics and 3 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.94 beat C4 Therapeutics' score of 0.24 indicating that Taysha Gene Therapies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment C4 Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Taysha Gene Therapies 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, AAPG or CCCC?

C4 Therapeutics has lower revenue, but higher earnings than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $574.12M 2.86 -$177.71M N/A N/A C4 Therapeutics $34.86M 12.37 -$104.99M -$1.19 N/A

Does the media prefer CCCC or CMPS?

In the previous week, C4 Therapeutics had 2 more articles in the media than Compass Pathways. MarketBeat recorded 4 mentions for C4 Therapeutics and 2 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 1.75 beat C4 Therapeutics' score of 0.24 indicating that Compass Pathways is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment C4 Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Compass Pathways 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor CCCC or TYRA?

In the previous week, C4 Therapeutics had 2 more articles in the media than Tyra Biosciences. MarketBeat recorded 4 mentions for C4 Therapeutics and 2 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.11 beat C4 Therapeutics' score of 0.24 indicating that Tyra Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment C4 Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Tyra Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

C4 Therapeutics (CCCC) Competitors

$3.90 +0.03 (+0.78%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$3.93 +0.03 (+0.79%)

As of 06/12/2026 07:00 PM Eastern

Compare

CCCC vs. AGIO, TSHA, AAPG, CMPS, and TYRA

Should you buy C4 Therapeutics stock or one of its competitors? MarketBeat compares C4 Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with C4 Therapeutics include Agios Pharmaceuticals (AGIO), Taysha Gene Therapies (TSHA), Ascentage Pharma Group International (AAPG), Compass Pathways (CMPS), and Tyra Biosciences (TYRA). These companies are all part of the "pharmaceutical products" industry.

How does C4 Therapeutics compare to Agios Pharmaceuticals?

Agios Pharmaceuticals (NASDAQ:AGIO) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

78.8% of C4 Therapeutics shares are owned by institutional investors. 5.4% of Agios Pharmaceuticals shares are owned by company insiders. Comparatively, 5.6% of C4 Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Agios Pharmaceuticals currently has a consensus price target of $40.89, indicating a potential upside of 38.79%. C4 Therapeutics has a consensus price target of $7.75, indicating a potential upside of 98.72%. Given C4 Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe C4 Therapeutics is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Agios Pharmaceuticals has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, C4 Therapeutics has a beta of 2.92, indicating that its share price is 192% more volatile than the broader market.

In the previous week, Agios Pharmaceuticals had 8 more articles in the media than C4 Therapeutics. MarketBeat recorded 12 mentions for Agios Pharmaceuticals and 4 mentions for C4 Therapeutics. Agios Pharmaceuticals' average media sentiment score of 0.76 beat C4 Therapeutics' score of 0.24 indicating that Agios Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
C4 Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

C4 Therapeutics has lower revenue, but higher earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	32.43	-$412.78M	-$7.25	N/A
C4 Therapeutics	$34.86M	12.37	-$104.99M	-$1.19	N/A

C4 Therapeutics has a net margin of -297.76% compared to Agios Pharmaceuticals' net margin of -639.84%. Agios Pharmaceuticals' return on equity of -34.11% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%
C4 Therapeutics	-297.76%	-50.68%	-33.22%

Summary

C4 Therapeutics beats Agios Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does C4 Therapeutics compare to Taysha Gene Therapies?

C4 Therapeutics (NASDAQ:CCCC) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

Taysha Gene Therapies has a net margin of 0.00% compared to C4 Therapeutics' net margin of -297.76%. C4 Therapeutics' return on equity of -50.68% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-297.76%	-50.68%	-33.22%
Taysha Gene Therapies	N/A	-56.07%	-40.16%

78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 5.6% of C4 Therapeutics shares are held by company insiders. Comparatively, 3.8% of Taysha Gene Therapies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

C4 Therapeutics has a beta of 2.92, indicating that its stock price is 192% more volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market.

In the previous week, C4 Therapeutics had 1 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 4 mentions for C4 Therapeutics and 3 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.94 beat C4 Therapeutics' score of 0.24 indicating that Taysha Gene Therapies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
C4 Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Taysha Gene Therapies	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

C4 Therapeutics has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$34.86M	12.37	-$104.99M	-$1.19	N/A
Taysha Gene Therapies	$7.47M	219.63	-$109M	-$0.38	N/A

C4 Therapeutics currently has a consensus price target of $7.75, suggesting a potential upside of 98.72%. Taysha Gene Therapies has a consensus price target of $11.64, suggesting a potential upside of 103.79%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, analysts clearly believe Taysha Gene Therapies is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

C4 Therapeutics beats Taysha Gene Therapies on 9 of the 17 factors compared between the two stocks.

How does C4 Therapeutics compare to Ascentage Pharma Group International?

Ascentage Pharma Group International (NASDAQ:AAPG) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

78.8% of C4 Therapeutics shares are owned by institutional investors. 5.6% of C4 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

C4 Therapeutics has lower revenue, but higher earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$574.12M	2.86	-$177.71M	N/A	N/A
C4 Therapeutics	$34.86M	12.37	-$104.99M	-$1.19	N/A

Ascentage Pharma Group International presently has a consensus price target of $46.43, indicating a potential upside of 163.80%. C4 Therapeutics has a consensus price target of $7.75, indicating a potential upside of 98.72%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, equities analysts plainly believe Ascentage Pharma Group International is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Ascentage Pharma Group International has a net margin of 0.00% compared to C4 Therapeutics' net margin of -297.76%. Ascentage Pharma Group International's return on equity of 0.00% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
C4 Therapeutics	-297.76%	-50.68%	-33.22%

Ascentage Pharma Group International has a beta of -0.05, indicating that its stock price is 105% less volatile than the broader market. Comparatively, C4 Therapeutics has a beta of 2.92, indicating that its stock price is 192% more volatile than the broader market.

In the previous week, Ascentage Pharma Group International had 1 more articles in the media than C4 Therapeutics. MarketBeat recorded 5 mentions for Ascentage Pharma Group International and 4 mentions for C4 Therapeutics. Ascentage Pharma Group International's average media sentiment score of 0.62 beat C4 Therapeutics' score of 0.24 indicating that Ascentage Pharma Group International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascentage Pharma Group International	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
C4 Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Ascentage Pharma Group International beats C4 Therapeutics on 10 of the 15 factors compared between the two stocks.

How does C4 Therapeutics compare to Compass Pathways?

C4 Therapeutics (NASDAQ:CCCC) and Compass Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

C4 Therapeutics currently has a consensus target price of $7.75, suggesting a potential upside of 98.72%. Compass Pathways has a consensus target price of $21.36, suggesting a potential upside of 76.85%. Given C4 Therapeutics' higher probable upside, analysts clearly believe C4 Therapeutics is more favorable than Compass Pathways.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

In the previous week, C4 Therapeutics had 2 more articles in the media than Compass Pathways. MarketBeat recorded 4 mentions for C4 Therapeutics and 2 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 1.75 beat C4 Therapeutics' score of 0.24 indicating that Compass Pathways is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
C4 Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compass Pathways	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Compass Pathways has a net margin of 0.00% compared to C4 Therapeutics' net margin of -297.76%. Compass Pathways' return on equity of -31.07% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-297.76%	-50.68%	-33.22%
Compass Pathways	N/A	-31.07%	-11.40%

78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 46.2% of Compass Pathways shares are owned by institutional investors. 5.6% of C4 Therapeutics shares are owned by company insiders. Comparatively, 2.8% of Compass Pathways shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

C4 Therapeutics has a beta of 2.92, indicating that its stock price is 192% more volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.5, indicating that its stock price is 150% more volatile than the broader market.

C4 Therapeutics has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$34.86M	12.37	-$104.99M	-$1.19	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A

Summary

C4 Therapeutics beats Compass Pathways on 9 of the 16 factors compared between the two stocks.

How does C4 Therapeutics compare to Tyra Biosciences?

C4 Therapeutics (NASDAQ:CCCC) and Tyra Biosciences (NASDAQ:TYRA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

C4 Therapeutics has a beta of 2.92, meaning that its share price is 192% more volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market.

C4 Therapeutics has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$34.86M	12.37	-$104.99M	-$1.19	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A

78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are owned by institutional investors. 5.6% of C4 Therapeutics shares are owned by company insiders. Comparatively, 12.5% of Tyra Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, C4 Therapeutics had 2 more articles in the media than Tyra Biosciences. MarketBeat recorded 4 mentions for C4 Therapeutics and 2 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.11 beat C4 Therapeutics' score of 0.24 indicating that Tyra Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
C4 Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tyra Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tyra Biosciences has a net margin of 0.00% compared to C4 Therapeutics' net margin of -297.76%. Tyra Biosciences' return on equity of -42.66% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-297.76%	-50.68%	-33.22%
Tyra Biosciences	N/A	-42.66%	-39.79%

C4 Therapeutics currently has a consensus target price of $7.75, suggesting a potential upside of 98.72%. Tyra Biosciences has a consensus target price of $46.00, suggesting a potential upside of 70.43%. Given C4 Therapeutics' higher possible upside, analysts clearly believe C4 Therapeutics is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

C4 Therapeutics and Tyra Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

Get C4 Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CCCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CCCC vs. The Competition

Export

Metric	C4 Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$431.21M	$3.39B	$6.72B	$12.07B
Dividend Yield	N/A	2.25%	2.67%	5.67%
P/E Ratio	-3.28	19.82	24.24	24.42
Price / Sales	12.37	177.23	481.04	86.26
Price / Cash	N/A	123.04	43.54	55.64
Price / Book	1.47	8.32	10.65	6.80
Net Income	-$104.99M	$23.94M	$3.57B	$338.00M
7 Day Performance	1.30%	3.53%	0.84%	2.68%
1 Month Performance	7.44%	-2.55%	-0.34%	1.56%
1 Year Performance	132.14%	44.82%	25.40%	30.59%

C4 Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CCCC C4 Therapeutics	1.846 of 5 stars	$3.90 +0.8%	$7.75 +98.7%	+132.1%	$431.21M	$34.86M	N/A	150	News Coverage Positive News
AGIO Agios Pharmaceuticals	3.5367 of 5 stars	$27.37 -0.2%	$41.44 +51.4%	-14.1%	$1.63B	$54.03M	N/A	390	News Coverage Analyst Forecast
TSHA Taysha Gene Therapies	3.2261 of 5 stars	$5.62 +3.4%	$11.64 +107.2%	+124.8%	$1.61B	$9.77M	N/A	180	News Coverage
AAPG Ascentage Pharma Group International	4.3067 of 5 stars	$17.18 -0.1%	$46.67 +171.7%	-44.1%	$1.60B	$82.10M	N/A	600	News Coverage Analyst Forecast Short Interest Increase Gap Up
CMPS Compass Pathways	3.4927 of 5 stars	$11.72 -0.1%	$21.36 +82.3%	+175.2%	$1.59B	N/A	N/A	120	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CCCC) was last updated on 6/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

C4 Therapeutics (CCCC) Competitors

CCCC vs. AGIO, TSHA, AAPG, CMPS, and TYRA

How does C4 Therapeutics compare to Agios Pharmaceuticals?

Summary

How does C4 Therapeutics compare to Taysha Gene Therapies?

Summary

How does C4 Therapeutics compare to Ascentage Pharma Group International?

Summary

How does C4 Therapeutics compare to Compass Pathways?

Summary

How does C4 Therapeutics compare to Tyra Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCCC vs. The Competition

C4 Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

C4 Therapeutics (CCCC) Competitors

CCCC vs. AGIO, TSHA, AAPG, CMPS, and TYRA

How does C4 Therapeutics compare to Agios Pharmaceuticals?

Do insiders and institutionals have more ownership in AGIO or CCCC?

Do analysts rate AGIO or CCCC?

Which has more risk and volatility, AGIO or CCCC?

Does the media favor AGIO or CCCC?

Which has preferable valuation and earnings, AGIO or CCCC?

Is AGIO or CCCC more profitable?

Summary

How does C4 Therapeutics compare to Taysha Gene Therapies?

Is CCCC or TSHA more profitable?

Do insiders and institutionals hold more shares of CCCC or TSHA?

Which has more volatility & risk, CCCC or TSHA?

Does the media refer more to CCCC or TSHA?

Which has better earnings & valuation, CCCC or TSHA?

Do analysts prefer CCCC or TSHA?

Summary

How does C4 Therapeutics compare to Ascentage Pharma Group International?

Do insiders & institutionals believe in AAPG or CCCC?

Which has stronger earnings and valuation, AAPG or CCCC?

Do analysts recommend AAPG or CCCC?

Is AAPG or CCCC more profitable?

Which has more volatility and risk, AAPG or CCCC?

Does the media favor AAPG or CCCC?

Summary

How does C4 Therapeutics compare to Compass Pathways?

Do analysts recommend CCCC or CMPS?

Does the media prefer CCCC or CMPS?

Is CCCC or CMPS more profitable?

Do institutionals and insiders hold more shares of CCCC or CMPS?

Which has more volatility & risk, CCCC or CMPS?

Which has better earnings and valuation, CCCC or CMPS?

Summary

How does C4 Therapeutics compare to Tyra Biosciences?

Which has more risk & volatility, CCCC or TYRA?

Which has higher earnings and valuation, CCCC or TYRA?

Do insiders and institutionals have more ownership in CCCC or TYRA?

Does the media favor CCCC or TYRA?

Is CCCC or TYRA more profitable?

Do analysts rate CCCC or TYRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCCC vs. The Competition

C4 Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools